

Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Grazoprevir / Elbasvir Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

117 16th Road

1685 Halfway house, Midrand, South Africa

Telephone : +27 11 655 3000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Long-term (chronic) aquatic hazard, Cat-

H410: Very toxic to aquatic life with long lasting

effects.

2.2 Label elements

egory 1

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

Signal word : Warning

Hazard statements : H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P273 Avoid release to the environment.



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

Response:

P391 Collect spillage.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Grazoprevir	1350462-55-3	STOT RE 2; H373 (Liver, Testis)	>= 1 - < 10
Elbasvir	1370468-36-2	Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 10	>= 2,5 - < 10

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : Wash with water and soap.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Metal oxides

Chlorine compounds Nitrogen oxides (NOx)

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres. Use only with adequate ventilation.

Local/Total ventilation : Use only with adequate Advice on safe handling : Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	OEL-RL	10 mg/m3	ZA OEL
	Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents			
Grazoprevir	1350462- 55-3	TWA	85 μg/m3 (OEB 3)	Internal
		Wipe limit	850 μg/100 cm ²	Internal
Elbasvir	1370468- 36-2	TWA	150 μg/m3 (OEB 2)	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Sodium chloride	Workers	Inhalation	Long-term systemic effects	2068,62 mg/m3
	Workers	Inhalation	Acute systemic effects	2068,62 mg/m3
	Workers	Skin contact	Long-term systemic effects	295,52 mg/kg bw/day
	Workers	Skin contact	Acute systemic effects	295,52 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	443,28 mg/m3



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

Cons	sumers Inha	Acute systemic effects	443,28 mg/m3
Cons	sumers Skin	Long-term systemic effects	126,65 mg/kg bw/day
Cons	sumers Skin	Acute systemic effects	126,65 mg/kg bw/day
Cons	sumers Inge	Long-term systemic effects	126,65 mg/kg bw/day
Cons	sumers Inge	Acute systemic effects	126,65 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Sodium chloride	Fresh water	5 mg/l
	Sewage treatment plant	500 mg/l
	Soil	4,86 mg/kg dry
		weight (d.w.)

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : powder



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

Colour : white

Odour : No data available
Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range Flash point

: Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Upper explosion limit / Upper

flammability limit

No data available

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility
Partition coefficient: n-

octanol/water

No data available

Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available

Particle size : No data available



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

Acute toxicity

Not classified based on available information.

Components:

Grazoprevir:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg

Elbasvir:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg

LD50 (Mouse): > 1.000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Grazoprevir:

Result : No skin irritation



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

Elbasvir:

Species : reconstructed human epidermis (RhE)

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Grazoprevir:

Species : Bovine cornea Result : No eye irritation

Elbasvir:

Species : Bovine cornea Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Grazoprevir:

Test Type : Local lymph node assay (LLNA)

Exposure routes : Dermal

Result : Not a skin sensitizer.

Elbasvir:

Test Type : Local lymph node assay (LLNA)

Exposure routes : Dermal Species : Mouse Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Grazoprevir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Application Route: Oral

Result: negative



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Elbasvir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Rat

Application Route: Oral

Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

Components:

Grazoprevir:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 400 mg/kg body weight

Result: negative

Test Type: Multi-generation study

Species: Rat

Application Route: Oral

Fertility: NOAEL: 400 mg/kg body weight

Result: No effects on fertility, No effects on foetal development

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight

Result: No effects on foetal development

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight

Result: No effects on foetal development

Test Type: Embryo-foetal development

Species: Rabbit



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

Application Route: Intravenous

Embryo-foetal toxicity: NOAEL: 100 mg/kg body weight

Result: No effects on foetal development

Elbasvir:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male and female

Application Route: Oral

Fertility: NOAEL: 1.000 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 1.000 mg/kg body weight

Result: No effects on early embryonic development

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 1.000 mg/kg body weight

Result: No effects on early embryonic development

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

Grazoprevir:

Target Organs : Liver, Testis

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Grazoprevir:

Species : Rat

NOAEL : 400 mg/kg Application Route : Oral Exposure time : 30 Days

Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 400 mg/kg
Application Route : Oral
Exposure time : 180 Days

Remarks : No significant adverse effects were reported

Species : Dog



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

NOAEL : 15 mg/kg LOAEL : 100 mg/kg Application Route : Oral Exposure time : 270 Days

Target Organs : Liver, Blood, Bone marrow, gallbladder, spleen, Testis

Species : Mouse

NOAEL : 200 mg/kg

LOAEL : 500 mg/kg

Application Route : Oral

Exposure time : 90 Days

Target Organs : Liver, Kidney, Blood

Species : Dog
NOAEL : 20 mg/kg
LOAEL : 600 mg/kg
Application Route : Oral
Exposure time : 30 Days
Target Organs : Blood, Testis

Species : Monkey NOAEL : 10 mg/kg Exposure time : 8 Days

Remarks : No significant adverse effects were reported

Elbasvir:

Species : Rat

NOAEL : 1.000 mg/kg

Application Route : Oral Exposure time : 180 d

Remarks : No significant adverse effects were reported

Species : Dog

NOAEL : 1.000 mg/kg
Application Route : Oral
Exposure time : 270 d

Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Grazoprevir:

Ingestion : Symptoms: Headache, Gastrointestinal disturbance

Elbasvir:

Ingestion : Symptoms: Headache, Abdominal pain, constipation, Nausea,

Fatigue, muscle pain, joint pain, Dizziness, Cough, Skin irrita-

tion, rhinitis, Drowsiness, nasal congestion



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

SECTION 12: Ecological information

12.1 Toxicity

Components:

Grazoprevir:

Toxicity to fish : LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10

mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

LC50 (Americamysis): 8,9 mg/l

Exposure time: 96 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 10

mg/l

Exposure time: 72 hrs

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 10

mg/l

Exposure time: 72 hrs

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 1.000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 1,3 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,98 mg/l

Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 5 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Elbasvir:



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 10 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility

LC50 (Menidia beryllina (Silverside)): > 10 mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

LC50 (Americamysis): 7,7 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (algae)): > 0,081 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 0,081

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 1.000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 271,9 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,0023 mg/l

Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0,84 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic

toxicity)

10



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

12.2 Persistence and degradability

Components:

Grazoprevir:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 66 % Exposure time: 28 d

Elbasvir:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 37 % Exposure time: 28 d

12.3 Bioaccumulative potential

Components:

Grazoprevir:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 7,62

Partition coefficient: n-

octanol/water

: log Pow: 3,72

Elbasvir:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 82 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 6,54

12.4 Mobility in soil

Components:

Grazoprevir:

Distribution among environ-

mental compartments

log Koc: 4,01

Elbasvir:

Distribution among environ-

mental compartments

log Koc: 5,24

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

12.6 Other adverse effects

Product:

Endocrine disrupting poten-

tial

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Elbasvir)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Elbasvir)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Elbasvir)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Elbasvir)

IATA : Environmentally hazardous substance, solid, n.o.s.

(Elbasvir)

14.3 Transport hazard class(es)



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

Class Subsidiary risks

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo :

aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

956

IATA (Passenger)

Packing instruction (passen- : 956

ger aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H373 : May cause damage to organs through prolonged or repeated

exposure if swallowed.

H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Aquatic Chronic : Long-term (chronic) aquatic hazard

STOT RE : Specific target organ toxicity - repeated exposure ZA OEL : South Africa. The Regulations for Hazardous Chemical

Agents, Occupational Exposure Limits

ZA OEL / OEL-RL : Occupational Exposure Limit Restricted limit - 8- hour expo-

sure or equivalent (12 hour shifts)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by



Grazoprevir / Elbasvir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.0 06.07.2024 76220-00029 Date of first issue: 17.03.2015

Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to : compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

Aquatic Chronic 1 H410 Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN



Grazoprevir / Elbasvir Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 6.0
 06.07.2024
 76220-00029
 Date of first issue: 17.03.2015